The antiatherogenic effect of allicin: possible mode of action.
about
Allicin induces the upregulation of ABCA1 expression via PPARγ/LXRα signaling in THP-1 macrophage-derived foam cellsThe effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in ratsTherapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds.Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice.Immunomodulation and anti-inflammatory effects of garlic compounds.A novel anti-inflammatory natural product from Sphaeranthus indicus inhibits expression of VCAM1 and ICAM1, and slows atherosclerosis progression independent of lipid changes.Nutraceutical therapies for atherosclerosis.Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: A randomized clinical trialGarlic: nature's protection against physiological threats.Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitroA review of the cardiovascular benefits and antioxidant properties of allicin.Garlic and cardioprotection: insights into the molecular mechanisms.Garlic in health and disease.Garlic (Allium sativum) stimulates lipopolysaccharide-induced tumor necrosis factor-alpha production from J774A.1 murine macrophages.Allicin protects rat cardiomyoblasts (H9c2 cells) from hydrogen peroxide-induced oxidative injury through inhibiting the generation of intracellular reactive oxygen species.Cholesterol-lowering effect of allicin on hypercholesterolemic ICR mice.Dietary spices as beneficial modulators of lipid profile in conditions of metabolic disorders and diseases.Neuroprotective effects of allicin on ischemia-reperfusion brain injury.Nutraceuticals as therapeutic agents for atherosclerosis.Protective effects of allicin on streptozotocin-induced diabetic nephropathy in rats.
P2860
Q33675106-6148649D-0921-4AC9-8EFF-ADDD0E9F208DQ34388041-4A832337-EB37-4198-8723-FAE8C8480FE8Q34395014-97BD0C54-6FC3-4E98-99AC-E6822D9E63E8Q35535851-477EB133-E0E4-4BE5-A51B-4546AF1C9BA9Q35563390-6F96B345-1273-4E2A-84B9-F12F340524E6Q35711283-16DAA534-4DDF-4AF4-9101-5B62DC7D47E3Q36068816-C13CEC32-3496-4756-A07C-B2645EB4FACDQ36181443-3850DD96-22EC-497B-AE6B-0A84B69A13D9Q37502883-233405B4-FB8C-43CE-953D-4C4D5971C4DCQ37593950-CA2E0254-0202-41E0-816A-EDA9B0D436F2Q38034196-67B86C5F-A3C8-46F8-B91E-BA5968E63CBBQ38112809-4A8AE9E7-D09C-4CB1-B43D-5643880C7042Q38204027-68CF26A8-441F-4F4F-9ED6-B23086DA4DE1Q38943153-1CDACA2A-442E-45C9-BA00-5CA59AE42343Q38983005-452321F3-1107-4BDC-8E70-340E674C6770Q41829959-146BCA03-C1E2-4B6E-8FBF-5C0095BF49D1Q46748330-7DEB7AEF-D0BF-4BC9-BBD0-431DC5B15585Q47132103-6616E398-8F62-4BD8-A904-649BBA32DD40Q49904156-BCC614C3-422C-4AC3-9DDF-20D2A955DF8AQ51282432-15CBAC99-665C-4A37-98F0-E6E8CF32858B
P2860
The antiatherogenic effect of allicin: possible mode of action.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The antiatherogenic effect of allicin: possible mode of action.
@en
The antiatherogenic effect of allicin: possible mode of action.
@nl
type
label
The antiatherogenic effect of allicin: possible mode of action.
@en
The antiatherogenic effect of allicin: possible mode of action.
@nl
prefLabel
The antiatherogenic effect of allicin: possible mode of action.
@en
The antiatherogenic effect of allicin: possible mode of action.
@nl
P2093
P2860
P356
P1433
P1476
The antiatherogenic effect of allicin: possible mode of action.
@en
P2093
Aharon Rabinkov
Aviv Shaish
Ayelet Gonen
David Mirelman
Dikla Ben-Shushan
Dror Harats
Esfir Ulman
Hana Levkovitz
Lev Weiner
Talia Miron
P2860
P304
P356
10.1159/000091330
P50
P577
2005-01-01T00:00:00Z